The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global companion animal health market reached a value of US$ 21.18 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 36.19 Billion by 2027, exhibiting a CAGR of 8.80% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Companion animal health refers to the regular monitoring of the health of companion animals to detect diseases and other conditions, which can put their lives in danger if left untreated. It includes the development of monoclonal antibody therapies, therapeutic vaccines, anti-neoplastic drugs, genomic tests, and digital technologies. At present, there is a significant rise in the number of pet parents around the world who are aware about the overall health and well-being of companion animals and routinely seek veterinary services.
Companion animal aging has led to a rise in the risk of tumors, obesity, osteoarthritis, cardiovascular diseases (CVDs), diabetes mellitus, and hepatic and renal diseases worldwide. This, in confluence with the growing awareness about the One Health (OH) approach initiative, which recognizes that public health is connected with animal health and the environment, represents one of the key factors creating a positive outlook for the market. This initiative is supported by the World Health Organization (WHO), Food and Agriculture Organization (FAO), and the American Veterinary Medical Association (AVMA). Moreover, having companion animals is associated with positive health benefits, including lower blood pressure, decrease anxiety, reduce cardiac arrhythmia, more psychological stability, and better well-being. Besides this, there is an increase in the utilization of animal-assisted therapy in numerous areas of human health care. This, coupled with the rising population of traditional companion animals, such as dogs and cats, is impelling the market growth. Apart from this, vaccination of companion animals, particularly dogs, against rabies helps prevent the disease in animals and humans. Furthermore, the increasing prevalence of zoonotic diseases across the globe is anticipated to facilitate the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global companion animal health market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on animal type, product and end user.
Breakup by Animal Type:
Breakup by Product:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agrolabo S.p.A., Boehringer Ingelheim, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, IDEXX Laboratories Inc., Indian Immunologicals Limited (National Dairy Development Board), Merck & Co. Inc., Norbrook Laboratories, Vetoquinol SA, Virbac and Zoetis Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Animal Type, Product, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agrolabo S.p.A., Boehringer Ingelheim, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, IDEXX Laboratories Inc., Indian Immunologicals Limited (National Dairy Development Board), Merck & Co. Inc., Norbrook Laboratories, Vetoquinol SA, Virbac and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at